Inhibrx Biosciences, Inc. (INBX) Stock Forecast & Price Target
Inhibrx Biosciences, Inc. · NASDAQ
$82.32+0.77 (+0.94%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Inhibrx Biosciences, Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $150.00 to $150.00, so the covering firms are broadly aligned. The average target of $150.00 sits 82% above the current $82.32. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.39 next quarter toward $-6.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Inhibrx Biosciences, Inc.
As of Jul, 1 of 2 firms rate INBX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
INBX EPS & revenue forecast
EPS · NEXT QUARTER
$-2.39
Range $-2.39 – $-2.39 · 1 analysts · +5% YoY
Next period, 1 analysts expect Inhibrx Biosciences, Inc. to earn $-2.39 a share (range $-2.39 – $-2.39), versus $-2.28 a year earlier. Full-year consensus is $-9.26, growing to $-6.30 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $57.2M next year.
Top analysts covering Inhibrx Biosciences, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INBX.
#1
Reni J. Benjamin
JMP Securities · Rank #290
Hold
No targeton INBX
Overall win rate
33%
+ Follow
#2
DA
Dara Azar
Stifel Nicolaus
Buy
$150.00+82.2% to target
Coverage
—
+ Follow
INBX stock forecast FAQ
What is INBX's average 12-month price target?+
The 1 analysts with a live target average $150.00 for Inhibrx Biosciences, Inc. over the next 12 months, ranging from a $150.00 high to a $150.00 low.
Is INBX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover INBX?+
2 analysts have an active rating on Inhibrx Biosciences, Inc., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering INBX?+
Among analysts who currently cover INBX, Reni J. Benjamin of JMP Securities has the strongest overall Quantellect track record (Rank #290). Their current call is Hold.
What is Inhibrx Biosciences, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-2.39 per share (range $-2.39 – $-2.39) across 1 analysts. Full-year EPS is projected at $-9.26, rising to $-6.30 the following year.
How much revenue is Inhibrx Biosciences, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $57.2M next year.
Have analysts been upgrading or downgrading INBX lately?+
As of Jul, 1 of 2 firms rate INBX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INBX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
